TuHURA Biosciences 10-Q: Merger, Warrants, and Preferred Stock

TL;DR

TuHURA 10-Q out: Merger agreement, Series C preferred stock & warrants active. Big moves ahead.

AI Summary

TuHURA Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business activities, including details on preferred stock and warrants. Notably, the filing references a Merger Agreement and subsequent events, indicating significant corporate actions during the reporting period.

Why It Matters

This filing provides insight into TuHURA Biosciences' financial health and strategic moves, including potential mergers and stock-related activities, which can impact investors and the company's future direction.

Risk Assessment

Risk Level: medium — The filing details preferred stock, warrants, and a merger agreement, suggesting potential financial complexities and strategic shifts that carry inherent risks.

Key Numbers

• 2024-09-30 — Reporting Period End Date (The 10-Q covers financial activities up to this date.)
• 2024-10-18 — Subsequent Event Date (Indicates a significant event occurred after the reporting period.)

Key Players & Entities

• TuHURA Biosciences, Inc. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of the reporting period
• Series C Preferred Stock (financial_instrument) — Mentioned in relation to dividends and merger agreement
• Merger Agreement (legal_document) — Key event referenced in the filing
• 2024-10-18 (date) — Date of a subsequent event

FAQ

Key Financial Figures

• $0.001 — Split") of its common stock, par value $0.001 per share. Effective at 12:03 a.m. East

Filing Documents

• hura-20240930.htm (10-Q) — 1160KB
• hura-ex31_1.htm (EX-31.1) — 17KB
• hura-ex31_2.htm (EX-31.2) — 16KB
• hura-ex32_1.htm (EX-32.1) — 9KB
• hura-ex32_2.htm (EX-32.2) — 9KB
• 0000950170-24-127199.txt ( ) — 5712KB
• hura-20240930.xsd (EX-101.SCH) — 1279KB
• hura-20240930_htm.xml (XML) — 702KB

- FINANCIAL INFORMATION

PART I. - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements. 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 25 Item 4

Controls and Procedures

Controls and Procedures. 25

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1. Legal Proceedings. 26 Item 1A. Risk Factors. 26 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities. 26 Item 3. Defaults Upon Senior Securities. 26 Item 4. Mine Safety Disclosures. 26 Item 5. Other Information. 26 Item 6. Exhibits. 27 i EXPLANATORY NOTE On October18, 2024 (the "Closing Date"), subsequent to the fiscal quarter ended September 30, 2024, the fiscal quarter to which this Quarterly Report on Form 10-Q (this "Report") relates, the Nevada corporation formerly known as Kintara Therapeutics, Inc. ("Kintara") consummated a previously announced merger transaction in accordance with the terms of that certain Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), by and among Kintara, Kayak Mergeco, Inc., a Delaware corporation and direct wholly owned subsidiary of Kintara ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("TuHURA"), pursuant to which, Merger Sub merged with and into TuHURA, with TuHURA surviving as a direct wholly owned subsidiary of Kintara and the surviving corporation of the merger (the "Merger"). In connection with the completion of the Merger, effective at 12:01 a.m. Eastern Time on the Closing Date, Kintara effected a 1-for-35 reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share. Effective at 12:03 a.m. Eastern Time on the Closing Date, Kintara completed the merger, and effective at 12:04 a.m. Eastern Time on the Closing Date, Kintara changed its name to "TuHURA Biosciences, Inc." Under the terms of the Merger, at the effective time of the Merger, (i) Kintara issued an aggregate of approximately 40,441,605 shares of Common Stock to TuHURA stockholders, based on an exchange ratio of 0.1789 (after giving effect to the Reverse Stock Split) shares of Kintara's common stock for each share of TuHURA common stock outst

Financi al Statements

Item 1. Financi al Statements. Kintara Therapeutics, Inc. Condensed Consolidated Interim Financial Statements (Unaudited) For the three months ended September 30, 2024 (expressed in US dollars unless otherwise noted) 1 Kintara Therapeutics, Inc. Condensed Consolidated Interim Balance Sheets (In thousands, except par value amounts) September, 2024 June 30, 2024 Note $ $ (unaudited) Assets Current assets Cash and cash equivalents 3,020 4,909 Prepaid expenses, taxes and other receivables 258 414 Clinical trial deposit 3 205 205 Total current assets 3,483 5,528 Property and equipment, net 5 657 674 Total assets 4,140 6,202 Liabilities Current liabilities Accounts payable and accrued liabilities 6 2,207 2,207 Related party payables 7 50 52 Total current liabilities 2,257 2,259 Milestone payment liability 10 188 186 Total liabilities 2,445 2,445 Stockholders' equity Preferred stock Authorized 5,000 shares, $ 0.001 par value Issued and outstanding 279 Series A shares at September 30, 2024 (June 30, 2024 – 279 ) 8 279 279 Nil Series C shares at September 30, 2024 (June 30, 2024 – 14 ) 8 — 9,973 Common stock Authorized 75,000 shares at September 30, 2024 (June 30, 2024 - 75,000 ), $ 0.001 par value Issued and outstanding 1,590 issued at September 30, 2024 (June 30, 2024 – 1,579 ) 8 2 2 Additional paid-in capital 8 163,445 153,358 Accumulated deficit ( 162,052 ) ( 159,876 ) Accumulated other comprehensive income 21 21 Total stockholders' equity 1,695 3,757 Total liabilities and stockholders' equity 4,140 6,202 Nature of operations, corporate history, going concern and management plans (note 1) Subsequent events (note 10) The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements. 2 Kintara Therapeutics, Inc. Condensed Co

View Full Filing

View this 10-Q filing on SEC EDGAR